Skip to main content
Top
Published in: Current Treatment Options in Oncology 12/2023

14-12-2023 | Skin Cancer

Non-Surgical Therapeutic Strategies for Non-Melanoma Skin Cancers

Authors: Qingyu Zeng, PhD, Chengqian Chen, PhD, Student, Diyan Chen, PhD, Student, Guolong Zhang, PhD, Xiuli Wang, PhD

Published in: Current Treatment Options in Oncology | Issue 12/2023

Login to get access

Opinion statement

Non-melanoma skin cancer (NMSC) is a globally prevalent skin disease, with basal cell carcinoma and squamous cell carcinoma accounting for 99% of NMSC cases. While surgical excision is the most common approach, numerous non-surgical therapies have rapidly advanced in recent years. In cases of low-risk NMSC, alongside surgical excision, priority should be given to physical therapy and photodynamic therapy. Physical therapy modalities, exemplified by electrodessication and curettage, emerge as safe and efficacious alternatives. In juxtaposition, photodynamic therapy, albeit relatively more costly, assumes preference for patients exhibiting heightened cosmetic concerns owing to the scarring risks inherent to physical therapy and surgical excision. Notably, the combination of curettage and photodynamic therapy has exhibited remarkable efficacy in the treatment of nodular basal cell carcinoma. Additionally, for elderly patients who may be intolerant to stimulation, modified photodynamic therapy offers an almost painless option. When surgery is unavoidable, photodynamic therapy can be a valuable adjunct, allowing for a more conservative surgical approach, either before or after the procedure. Radiotherapy holds a prominent role in comprehensive treatment strategies, especially for patients ineligible for surgical intervention or those with lesions precluding further surgical measures. In cases of NMSC exhibiting perineural invasion or lymphovascular involvement, adjunctive radiotherapy is advised; however, potential adverse effects necessitate careful consideration. For advanced NMSC cases where surgery and physical therapy fall short, immunotherapy provide viable solutions. Systemic therapy employing Hedgehog pathway inhibitors can be considered for patients with distant metastatic basal cell carcinoma, despite its low incidence, or individuals with locally advanced lesions who are not surgical candidates, or those encountering recurrences after resection and radiotherapy. However, close monitoring of disease progression and adverse reactions is crucial. In this evolving landscape of NMSC treatment, personalized and multidisciplinary approaches are key, ensuring optimal outcomes while prioritizing patient safety and satisfaction.
Literature
2.
go back to reference Tanese K, Nakamura Y, Hirai I, Funakoshi T. Updates on the Systemic treatment of advanced non-melanoma skin cancer. Front Med (Lausanne). 2019;6:160.PubMedCrossRef Tanese K, Nakamura Y, Hirai I, Funakoshi T. Updates on the Systemic treatment of advanced non-melanoma skin cancer. Front Med (Lausanne). 2019;6:160.PubMedCrossRef
3.
go back to reference Hu W, Fang L, Ni R, Zhang H, Pan G. Changing trends in the disease burden of non-melanoma skin cancer globally from 1990 to 2019 and its predicted level in 25 years. BMC Cancer. 2022;22(1):836.PubMedPubMedCentralCrossRef Hu W, Fang L, Ni R, Zhang H, Pan G. Changing trends in the disease burden of non-melanoma skin cancer globally from 1990 to 2019 and its predicted level in 25 years. BMC Cancer. 2022;22(1):836.PubMedPubMedCentralCrossRef
4.
go back to reference Lv R, Sun Q. A network meta-analysis of non-melanoma skin cancer (NMSC) treatments: efficacy and safety assessment. J Cell Biochem. 2017;118(11):3686–95.PubMedCrossRef Lv R, Sun Q. A network meta-analysis of non-melanoma skin cancer (NMSC) treatments: efficacy and safety assessment. J Cell Biochem. 2017;118(11):3686–95.PubMedCrossRef
5.
go back to reference St Claire K, Hoover A, Ashack K, Khachemoune A. Extramammary Paget disease. Dermatol Online J. 2019;25(4):13030/qt7qg8g292. St Claire K, Hoover A, Ashack K, Khachemoune A. Extramammary Paget disease. Dermatol Online J. 2019;25(4):13030/qt7qg8g292.
6.
go back to reference Win TS, Tsao H. Keratinocytic skin cancers-Update on the molecular biology. Cancer. 2023;129(6):836–44.PubMedCrossRef Win TS, Tsao H. Keratinocytic skin cancers-Update on the molecular biology. Cancer. 2023;129(6):836–44.PubMedCrossRef
7.
go back to reference Lai M, Pampena R, Cornacchia L, Odorici G, Piccerillo A, Pellacani G, et al. Cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemia: a systematic review of the literature. Int J Dermatol. 2022;61(5):548–57.PubMedCrossRef Lai M, Pampena R, Cornacchia L, Odorici G, Piccerillo A, Pellacani G, et al. Cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemia: a systematic review of the literature. Int J Dermatol. 2022;61(5):548–57.PubMedCrossRef
8.
go back to reference Hernandez LE, Mohsin N, Levin N, Dreyfuss I, Frech F, Nouri K. Basal cell carcinoma: An updated review of pathogenesis and treatment options. Dermatol Ther. 2022;35(6):e15501.PubMedCrossRef Hernandez LE, Mohsin N, Levin N, Dreyfuss I, Frech F, Nouri K. Basal cell carcinoma: An updated review of pathogenesis and treatment options. Dermatol Ther. 2022;35(6):e15501.PubMedCrossRef
9.
go back to reference Khandelwal AR, Echanique KA, St John M, Nathan CA. Cutaneous cancer biology. Otolaryngol Clin North Am. 2021;54(2):259–69.PubMedCrossRef Khandelwal AR, Echanique KA, St John M, Nathan CA. Cutaneous cancer biology. Otolaryngol Clin North Am. 2021;54(2):259–69.PubMedCrossRef
10.
go back to reference Malvehy J, Pellacani G. Dermoscopy, confocal microscopy and other non-invasive tools for the diagnosis of non-melanoma skin cancers and other skin conditions. Acta Derm Venereol. 2017;Suppl 218:22–30.PubMed Malvehy J, Pellacani G. Dermoscopy, confocal microscopy and other non-invasive tools for the diagnosis of non-melanoma skin cancers and other skin conditions. Acta Derm Venereol. 2017;Suppl 218:22–30.PubMed
11.
go back to reference Werner RN, Stockfleth E, Connolly SM, Correia O, Erdmann R, Foley P, et al. Evidence- and consensus-based (S3) guidelines for the treatment of actinic keratosis - International League of Dermatological Societies in cooperation with the European Dermatology Forum - Short version. J Eur Acad Dermatol Venereol. 2015;29(11):2069–79.PubMedCrossRef Werner RN, Stockfleth E, Connolly SM, Correia O, Erdmann R, Foley P, et al. Evidence- and consensus-based (S3) guidelines for the treatment of actinic keratosis - International League of Dermatological Societies in cooperation with the European Dermatology Forum - Short version. J Eur Acad Dermatol Venereol. 2015;29(11):2069–79.PubMedCrossRef
12.
go back to reference Ramelyte E, Nageli MC, Hunger R, Merat R, Gaide O, Navarini AA, et al. Swiss recommendations for cutaneous basal cell carcinoma. Dermatology. 2023;239(1):122–31.PubMedCrossRef Ramelyte E, Nageli MC, Hunger R, Merat R, Gaide O, Navarini AA, et al. Swiss recommendations for cutaneous basal cell carcinoma. Dermatology. 2023;239(1):122–31.PubMedCrossRef
14.
go back to reference Backman EJ, Polesie S, Berglund S, Gillstedt M, Sjoholm A, Modin M, et al. Curettage vs. cryosurgery for superficial basal cell carcinoma: a prospective, randomised and controlled trial. J Eur Acad Dermatol Venereol. 2022;36(10):1758–65.PubMedPubMedCentralCrossRef Backman EJ, Polesie S, Berglund S, Gillstedt M, Sjoholm A, Modin M, et al. Curettage vs. cryosurgery for superficial basal cell carcinoma: a prospective, randomised and controlled trial. J Eur Acad Dermatol Venereol. 2022;36(10):1758–65.PubMedPubMedCentralCrossRef
15.
go back to reference Fournier S, Laroche A, Leblanc M, Bourgeault E, Ulrich Singbo MN, Turcotte S, et al. Prospective Clinical Trial comparing curettage and cryosurgery to curettage and electrodesiccation in the management of minimally invasive basal and squamous cell carcinomas [Formula: see text]. J Cutan Med Surg. 2020;24(6):596–600.PubMedCrossRef Fournier S, Laroche A, Leblanc M, Bourgeault E, Ulrich Singbo MN, Turcotte S, et al. Prospective Clinical Trial comparing curettage and cryosurgery to curettage and electrodesiccation in the management of minimally invasive basal and squamous cell carcinomas [Formula: see text]. J Cutan Med Surg. 2020;24(6):596–600.PubMedCrossRef
16.
go back to reference Srivastava P, Kumar A. An experimental study to characterise the role of multihole nozzle in adjuvant assisted cryospray. Int J Therm Sci. 2023;183:107838.CrossRef Srivastava P, Kumar A. An experimental study to characterise the role of multihole nozzle in adjuvant assisted cryospray. Int J Therm Sci. 2023;183:107838.CrossRef
17.
go back to reference Paasch U, Zidane M, Baron JM, Bund T, Cappius HJ, Drosner M, et al. S2k guideline: Laser therapy of the skin. J Dtsch Dermatol Ges. 2022;20(9):1248–67.PubMed Paasch U, Zidane M, Baron JM, Bund T, Cappius HJ, Drosner M, et al. S2k guideline: Laser therapy of the skin. J Dtsch Dermatol Ges. 2022;20(9):1248–67.PubMed
18.
go back to reference Benson TA, Hibler BP, Kotliar D, Avram M. Nonablative fractional laser treatment is associated with a decreased risk of subsequent facial keratinocyte carcinoma development. Dermatol Surg. 2023;49(2):149–54.PubMedCrossRef Benson TA, Hibler BP, Kotliar D, Avram M. Nonablative fractional laser treatment is associated with a decreased risk of subsequent facial keratinocyte carcinoma development. Dermatol Surg. 2023;49(2):149–54.PubMedCrossRef
19.
20.
go back to reference Collins A, Savas J, Doerfler L. Nonsurgical treatments for nonmelanoma skin cancer. Dermatol Clin. 2019;37(4):435–41.PubMedCrossRef Collins A, Savas J, Doerfler L. Nonsurgical treatments for nonmelanoma skin cancer. Dermatol Clin. 2019;37(4):435–41.PubMedCrossRef
21.
go back to reference Schmults CD, Blitzblau R, Aasi SZ, Alam M, Andersen JS, Baumann BC, et al. NCCN guidelines(R) insights: squamous cell skin cancer, Version 1.2022. J Natl Compr Canc Netw. 2021;19(12):1382–94.PubMedCrossRef Schmults CD, Blitzblau R, Aasi SZ, Alam M, Andersen JS, Baumann BC, et al. NCCN guidelines(R) insights: squamous cell skin cancer, Version 1.2022. J Natl Compr Canc Netw. 2021;19(12):1382–94.PubMedCrossRef
23.
go back to reference Locke J, Karimpour S, Young G, Lockett MA, Perez CA. Radiotherapy for epithelial skin cancer. Int J Radiat Oncol Biol Phys. 2001;51(3):748–55.PubMedCrossRef Locke J, Karimpour S, Young G, Lockett MA, Perez CA. Radiotherapy for epithelial skin cancer. Int J Radiat Oncol Biol Phys. 2001;51(3):748–55.PubMedCrossRef
24.
go back to reference Ceovic R, Petkovic M, Mokos ZB, Kostovic K. Nonsurgical treatment of nonmelanoma skin cancer in the mature patient. Clin Dermatol. 2018;36(2):177–87.PubMedCrossRef Ceovic R, Petkovic M, Mokos ZB, Kostovic K. Nonsurgical treatment of nonmelanoma skin cancer in the mature patient. Clin Dermatol. 2018;36(2):177–87.PubMedCrossRef
25.
go back to reference De Felice F, Musio D, De Falco D, Grapulin L, Magnante AL, Caiazzo R, et al. Definitive weekly hypofractionated radiotherapy in cutaneous squamous cell carcinoma: response rates and outcomes in elderly patients unfit for surgery. Int J Dermatol. 2022;61(8):911–5.PubMedCrossRef De Felice F, Musio D, De Falco D, Grapulin L, Magnante AL, Caiazzo R, et al. Definitive weekly hypofractionated radiotherapy in cutaneous squamous cell carcinoma: response rates and outcomes in elderly patients unfit for surgery. Int J Dermatol. 2022;61(8):911–5.PubMedCrossRef
26.
go back to reference Vaishampayan P, Curiel-Lewandrowski C, Dickinson SE. Review: PD-L1 as an emerging target in the treatment and prevention of keratinocytic skin cancer. Mol Carcinog. 2023;62(1):52–61.PubMedCrossRef Vaishampayan P, Curiel-Lewandrowski C, Dickinson SE. Review: PD-L1 as an emerging target in the treatment and prevention of keratinocytic skin cancer. Mol Carcinog. 2023;62(1):52–61.PubMedCrossRef
27.
go back to reference Ghidini A, Santangelo D, Vaccaro G, Chillura M, Petrelli F. Cemiplimab in cutaneous squamous cell carcinomas (SCC): an overview and a clinical case. Oral Oncol. 2022;128:105847.PubMedCrossRef Ghidini A, Santangelo D, Vaccaro G, Chillura M, Petrelli F. Cemiplimab in cutaneous squamous cell carcinomas (SCC): an overview and a clinical case. Oral Oncol. 2022;128:105847.PubMedCrossRef
28.
go back to reference Hughes BGM, Munoz-Couselo E, Mortier L, Bratland A, Gutzmer R, Roshdy O, et al. Corrigendum to 'Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial: [Annals of Oncology Volume 32, Issue 10, October 2021, Pages 1276–1285]. Ann Oncol. 2022;33(8):853. Hughes BGM, Munoz-Couselo E, Mortier L, Bratland A, Gutzmer R, Roshdy O, et al. Corrigendum to 'Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial: [Annals of Oncology Volume 32, Issue 10, October 2021, Pages 1276–1285]. Ann Oncol. 2022;33(8):853.
29.
go back to reference Zhang H, Zhong A, Chen J. Immune checkpoint inhibitors in advanced cutaneous squamous cell carcinoma: a systemic review and meta-analysis. Skin Res Technol. 2023;29(1):e13229.PubMedCrossRef Zhang H, Zhong A, Chen J. Immune checkpoint inhibitors in advanced cutaneous squamous cell carcinoma: a systemic review and meta-analysis. Skin Res Technol. 2023;29(1):e13229.PubMedCrossRef
30.
go back to reference Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, et al. PD-1 Blockade with pembrolizumab in advanced merkel-cell carcinoma. N Engl J Med. 2016;374(26):2542–52.PubMedPubMedCentralCrossRef Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, et al. PD-1 Blockade with pembrolizumab in advanced merkel-cell carcinoma. N Engl J Med. 2016;374(26):2542–52.PubMedPubMedCentralCrossRef
32.
go back to reference Veron M, Chevret S, Grob JJ, Beylot-Barry M, Saiag P, Flechon A, et al. Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSe NIVOLUMAB trial. Eur J Cancer. 2022;177:103–11.PubMedCrossRef Veron M, Chevret S, Grob JJ, Beylot-Barry M, Saiag P, Flechon A, et al. Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSe NIVOLUMAB trial. Eur J Cancer. 2022;177:103–11.PubMedCrossRef
33.
go back to reference Wilken R, Criscito M, Pavlick AC, Stevenson ML, Carucci JA. Current Research in melanoma and aggressive nonmelanoma skin cancer. Facial Plast Surg. 2020;36(2):200–10.PubMedCrossRef Wilken R, Criscito M, Pavlick AC, Stevenson ML, Carucci JA. Current Research in melanoma and aggressive nonmelanoma skin cancer. Facial Plast Surg. 2020;36(2):200–10.PubMedCrossRef
34.•
go back to reference Clingan P, Ladwa R, Brungs D, Harris DL, McGrath M, Arnold S, et al. Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma. J Immunother Cancer. 2023;11(10):e007637. https://doi.org/10.1136/jitc-2023-007637. A Phase I clinical trial, for the first time, assessed the efficacy and safety of a PD-L1-blocking antibody in metastatic cutaneous squamous cell carcinoma. Clingan P, Ladwa R, Brungs D, Harris DL, McGrath M, Arnold S, et al. Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma. J Immunother Cancer. 2023;11(10):e007637. https://​doi.​org/​10.​1136/​jitc-2023-007637. A Phase I clinical trial, for the first time, assessed the efficacy and safety of a PD-L1-blocking antibody in metastatic cutaneous squamous cell carcinoma.
35.
go back to reference Bennardo L, Bennardo F, Giudice A, Passante M, Dastoli S, Morrone P, et al. Local Chemotherapy as an adjuvant treatment in unresectable squamous cell carcinoma: what do we know so far? Curr Oncol. 2021;28(4):2317–25.PubMedPubMedCentralCrossRef Bennardo L, Bennardo F, Giudice A, Passante M, Dastoli S, Morrone P, et al. Local Chemotherapy as an adjuvant treatment in unresectable squamous cell carcinoma: what do we know so far? Curr Oncol. 2021;28(4):2317–25.PubMedPubMedCentralCrossRef
36.
go back to reference Huang JW, Kuo CL, Wang LT, Ma KS, Huang WY, Liu FC, et al. Case report: in situ vaccination by autologous CD16(+) dendritic cells and anti-PD-L 1 antibody synergized with radiotherapy to boost T cells-mediated antitumor efficacy in a psoriatic patient with cutaneous squamous cell carcinoma. Front Immunol. 2021;12:752563.PubMedPubMedCentralCrossRef Huang JW, Kuo CL, Wang LT, Ma KS, Huang WY, Liu FC, et al. Case report: in situ vaccination by autologous CD16(+) dendritic cells and anti-PD-L 1 antibody synergized with radiotherapy to boost T cells-mediated antitumor efficacy in a psoriatic patient with cutaneous squamous cell carcinoma. Front Immunol. 2021;12:752563.PubMedPubMedCentralCrossRef
37.
go back to reference Savoia P, Cremona O, Fava P. New perspectives in the pharmacological treatment of non-melanoma skin cancer. Curr Drug Targets. 2016;17(3):353–74.PubMedCrossRef Savoia P, Cremona O, Fava P. New perspectives in the pharmacological treatment of non-melanoma skin cancer. Curr Drug Targets. 2016;17(3):353–74.PubMedCrossRef
38.
go back to reference Di Nardo L, Pellegrini C, Di Stefani A, Del Regno L, Sollena P, Piccerillo A, et al. Molecular genetics of cutaneous squamous cell carcinoma: perspective for treatment strategies. J Eur Acad Dermatol Venereol. 2020;34(5):932–41.PubMedCrossRef Di Nardo L, Pellegrini C, Di Stefani A, Del Regno L, Sollena P, Piccerillo A, et al. Molecular genetics of cutaneous squamous cell carcinoma: perspective for treatment strategies. J Eur Acad Dermatol Venereol. 2020;34(5):932–41.PubMedCrossRef
39.
go back to reference Picard A, Pedeutour F, Peyrade F, Saudes L, Duranton-Tanneur V, Chamorey E, et al. Association of oncogenic mutations in patients with advanced cutaneous squamous cell carcinomas treated with cetuximab. JAMA Dermatol. 2017;153(4):291–8.PubMedCrossRef Picard A, Pedeutour F, Peyrade F, Saudes L, Duranton-Tanneur V, Chamorey E, et al. Association of oncogenic mutations in patients with advanced cutaneous squamous cell carcinomas treated with cetuximab. JAMA Dermatol. 2017;153(4):291–8.PubMedCrossRef
40.
go back to reference Xu G, Fang J, Xu J, Shen Z, Huang C, Jiang Y. Expression and significance of mammalian target of rapamycin in cutaneous squamous cell carcinoma and precancerous lesions. Bioengineered. 2021;12(2):9930–8.PubMedPubMedCentralCrossRef Xu G, Fang J, Xu J, Shen Z, Huang C, Jiang Y. Expression and significance of mammalian target of rapamycin in cutaneous squamous cell carcinoma and precancerous lesions. Bioengineered. 2021;12(2):9930–8.PubMedPubMedCentralCrossRef
41.
go back to reference Chen S, Nakahara T, Uchi H, Takeuchi S, Takahara M, Kido M, et al. Immunohistochemical analysis of the mammalian target of rapamycin signalling pathway in extramammary Paget’s disease. Br J Dermatol. 2009;161(2):357–63.PubMedCrossRef Chen S, Nakahara T, Uchi H, Takeuchi S, Takahara M, Kido M, et al. Immunohistochemical analysis of the mammalian target of rapamycin signalling pathway in extramammary Paget’s disease. Br J Dermatol. 2009;161(2):357–63.PubMedCrossRef
42.
go back to reference Gluck M, Hodak E, Davidovici B. Mammalian target of rapamycin inhibitors for prolonged secondary prevention of nonmelanoma skin cancer in solid organ transplant recipients. Dermatol Ther. 2022;35(8):e15649.PubMedCrossRef Gluck M, Hodak E, Davidovici B. Mammalian target of rapamycin inhibitors for prolonged secondary prevention of nonmelanoma skin cancer in solid organ transplant recipients. Dermatol Ther. 2022;35(8):e15649.PubMedCrossRef
43.
go back to reference Salgo R, Gossmann J, Schofer H, Kachel HG, Kuck J, Geiger H, et al. Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am J Transplant. 2010;10(6):1385–93.PubMedCrossRef Salgo R, Gossmann J, Schofer H, Kachel HG, Kuck J, Geiger H, et al. Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am J Transplant. 2010;10(6):1385–93.PubMedCrossRef
44.
go back to reference Gu YH, Du JX, Ma ML. Sirolimus and non-melanoma skin cancer prevention after kidney transplantation: a meta-analysis. Asian Pac J Cancer Prev. 2012;13(9):4335–9.PubMedCrossRef Gu YH, Du JX, Ma ML. Sirolimus and non-melanoma skin cancer prevention after kidney transplantation: a meta-analysis. Asian Pac J Cancer Prev. 2012;13(9):4335–9.PubMedCrossRef
45.•
go back to reference Song Y, Guerrero-Juarez CF, Chen Z, Tang Y, Ma X, Lv C, et al. The Msi1-mTOR pathway drives the pathogenesis of mammary and extramammary Paget's disease. Cell Res. 2020;30(10):854–72. First report demonstrated that mTOR inhibitor rapamycin improved symptoms associated with extramammary Paget's disease. Song Y, Guerrero-Juarez CF, Chen Z, Tang Y, Ma X, Lv C, et al. The Msi1-mTOR pathway drives the pathogenesis of mammary and extramammary Paget's disease. Cell Res. 2020;30(10):854–72. First report demonstrated that mTOR inhibitor rapamycin improved symptoms associated with extramammary Paget's disease.
46.
go back to reference Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171–9.PubMedPubMedCentralCrossRef Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171–9.PubMedPubMedCentralCrossRef
47.
go back to reference Zhu H, Lewis DJ. Topical hedgehog inhibitors for basal cell carcinoma: how far away are we? Expert Opin Pharmacother. 2022;23(6):739–40.PubMedCrossRef Zhu H, Lewis DJ. Topical hedgehog inhibitors for basal cell carcinoma: how far away are we? Expert Opin Pharmacother. 2022;23(6):739–40.PubMedCrossRef
49.
go back to reference Tang T, Tang JY, Li D, Reich M, Callahan CA, Fu L, et al. Targeting superficial or nodular Basal cell carcinoma with topically formulated small molecule inhibitor of smoothened. Clin Cancer Res. 2011;17(10):3378–87.PubMedPubMedCentralCrossRef Tang T, Tang JY, Li D, Reich M, Callahan CA, Fu L, et al. Targeting superficial or nodular Basal cell carcinoma with topically formulated small molecule inhibitor of smoothened. Clin Cancer Res. 2011;17(10):3378–87.PubMedPubMedCentralCrossRef
50.
51.
go back to reference Wang D, Wang P, Li C, Zhou Z, Zhang L, Zhang G, et al. Efficacy and safety of HpD-PDT for Extramammary Paget’s Disease refractory to conventional therapy: a prospective, open-label and single arm pilot study. Photodiagnosis Photodyn Ther. 2022;37:102670.PubMedCrossRef Wang D, Wang P, Li C, Zhou Z, Zhang L, Zhang G, et al. Efficacy and safety of HpD-PDT for Extramammary Paget’s Disease refractory to conventional therapy: a prospective, open-label and single arm pilot study. Photodiagnosis Photodyn Ther. 2022;37:102670.PubMedCrossRef
52.
go back to reference Gomez C, Cobos P, Alberdi E. Methyl aminolevulinate photodynamic therapy after partial debulking in the treatment of superficial and nodular basal cell carcinoma: 3-years follow-up. Photodiagnosis Photodyn Ther. 2021;33:102176.PubMedCrossRef Gomez C, Cobos P, Alberdi E. Methyl aminolevulinate photodynamic therapy after partial debulking in the treatment of superficial and nodular basal cell carcinoma: 3-years follow-up. Photodiagnosis Photodyn Ther. 2021;33:102176.PubMedCrossRef
53.
go back to reference Yu N, Wu L, Su J, Chen M, Lu L, Huang K, et al. Photodynamic therapy combined with surgery versus Mohs micrographic surgery for the treatment of difficult-to-treat basal cell carcinoma: a retrospective clinical study. J Dermatolog Treat. 2023;34(1):2200871.PubMedCrossRef Yu N, Wu L, Su J, Chen M, Lu L, Huang K, et al. Photodynamic therapy combined with surgery versus Mohs micrographic surgery for the treatment of difficult-to-treat basal cell carcinoma: a retrospective clinical study. J Dermatolog Treat. 2023;34(1):2200871.PubMedCrossRef
54.
go back to reference Azzopardi EA, Abdelrahman W, Azzopardi E, O’Leary B, Yarrow J, Miles N, et al. Treatment of cutaneous basal cell carcinoma with combined laser extirpation and methyl aminolevulinic acid: five-year success rates. Ann R Coll Surg Engl. 2021;103(4):263–71.PubMedPubMedCentralCrossRef Azzopardi EA, Abdelrahman W, Azzopardi E, O’Leary B, Yarrow J, Miles N, et al. Treatment of cutaneous basal cell carcinoma with combined laser extirpation and methyl aminolevulinic acid: five-year success rates. Ann R Coll Surg Engl. 2021;103(4):263–71.PubMedPubMedCentralCrossRef
55.
go back to reference Adnane F, El-Zayat E, Fahmy HM. The combinational application of photodynamic therapy and nanotechnology in skin cancer treatment: a review. Tissue Cell. 2022;77:101856.PubMedCrossRef Adnane F, El-Zayat E, Fahmy HM. The combinational application of photodynamic therapy and nanotechnology in skin cancer treatment: a review. Tissue Cell. 2022;77:101856.PubMedCrossRef
56.•
go back to reference Rao H, Cartron A, Khachemoune A. Nonsurgical treatment options for basal cell carcinoma. JAAPA. 2022;35(11):38–43. A large clinical study reported a three-year follow-up on the use of photodynamic therapy in combination with curettage for the treatment of superficial and nodular basal cell carcinoma. Rao H, Cartron A, Khachemoune A. Nonsurgical treatment options for basal cell carcinoma. JAAPA. 2022;35(11):38–43. A large clinical study reported a three-year follow-up on the use of photodynamic therapy in combination with curettage for the treatment of superficial and nodular basal cell carcinoma.
57.
go back to reference Mansuri P, Tabaie SM, Naderi MS, Kebriti K, EsmaeeliDjavid G, Shirkavand A. Systemic photodynamic therapy with chlorine e6 as a photosensitizer for the treatment of nodular BCC: a case report. J Lasers Med Sci. 2022;13:e44.PubMedPubMedCentralCrossRef Mansuri P, Tabaie SM, Naderi MS, Kebriti K, EsmaeeliDjavid G, Shirkavand A. Systemic photodynamic therapy with chlorine e6 as a photosensitizer for the treatment of nodular BCC: a case report. J Lasers Med Sci. 2022;13:e44.PubMedPubMedCentralCrossRef
58.
go back to reference Ji J, Zhang Y, Chen WR, Wang X. DC vaccine generated by ALA-PDT-induced immunogenic apoptotic cells for skin squamous cell carcinoma. Oncoimmunology. 2016;5(6):e1072674.PubMedCrossRef Ji J, Zhang Y, Chen WR, Wang X. DC vaccine generated by ALA-PDT-induced immunogenic apoptotic cells for skin squamous cell carcinoma. Oncoimmunology. 2016;5(6):e1072674.PubMedCrossRef
59.
go back to reference Zhao Z, Zhang H, Zeng Q, Wang P, Zhang G, Ji J, et al. Exosomes from 5-aminolevulinic acid photodynamic therapy-treated squamous carcinoma cells promote dendritic cell maturation. Photodiagnosis Photodyn Ther. 2020;30:101746.PubMedCrossRef Zhao Z, Zhang H, Zeng Q, Wang P, Zhang G, Ji J, et al. Exosomes from 5-aminolevulinic acid photodynamic therapy-treated squamous carcinoma cells promote dendritic cell maturation. Photodiagnosis Photodyn Ther. 2020;30:101746.PubMedCrossRef
60.•
go back to reference Zeng Q, Yang J, Ji J, Wang P, Zhang L, Yan G, et al. PD-L1 blockade potentiates the antitumor effects of ALA-PDT and optimizes the tumor microenvironment in cutaneous squamous cell carcinoma. Oncoimmunology. 2022;11(1):2061396. The study confirmed that PD-L1 blockade enhances the anti-tumor effects of photodynamic therapy in both primary and distant cutaneous squamous cell carcinoma tumors. Zeng Q, Yang J, Ji J, Wang P, Zhang L, Yan G, et al. PD-L1 blockade potentiates the antitumor effects of ALA-PDT and optimizes the tumor microenvironment in cutaneous squamous cell carcinoma. Oncoimmunology. 2022;11(1):2061396. The study confirmed that PD-L1 blockade enhances the anti-tumor effects of photodynamic therapy in both primary and distant cutaneous squamous cell carcinoma tumors.
61.
go back to reference Zeng Q, Zhou C, Zhang Y, Yan G, Wang X. Modified 5-aminolevulinic acid photodynamic therapy reduces pain and improves therapeutic effects in cutaneous squamous cell carcinoma mouse model. Lasers Surg Med. 2022;54(5):804–12.PubMedCrossRef Zeng Q, Zhou C, Zhang Y, Yan G, Wang X. Modified 5-aminolevulinic acid photodynamic therapy reduces pain and improves therapeutic effects in cutaneous squamous cell carcinoma mouse model. Lasers Surg Med. 2022;54(5):804–12.PubMedCrossRef
62.
go back to reference Zheng J, Liu W, Zhou Z, Cao Z, Zhao Z, Wang X, et al. Successful treatment of non-melanoma skin cancer in three patients with Xeroderma Pigmentosum by modified ALA-PDT. Photodiagnosis Photodyn Ther. 2023;43:103694.PubMedCrossRef Zheng J, Liu W, Zhou Z, Cao Z, Zhao Z, Wang X, et al. Successful treatment of non-melanoma skin cancer in three patients with Xeroderma Pigmentosum by modified ALA-PDT. Photodiagnosis Photodyn Ther. 2023;43:103694.PubMedCrossRef
63.
go back to reference Liao C, Zhang G, Wang P, Sun X, Wang X. Combination curettage and modified ALA-PDT for multiple basal cell carcinomas of the face and head. Photodiagnosis Photodyn Ther. 2021;35:102393.PubMedCrossRef Liao C, Zhang G, Wang P, Sun X, Wang X. Combination curettage and modified ALA-PDT for multiple basal cell carcinomas of the face and head. Photodiagnosis Photodyn Ther. 2021;35:102393.PubMedCrossRef
Metadata
Title
Non-Surgical Therapeutic Strategies for Non-Melanoma Skin Cancers
Authors
Qingyu Zeng, PhD
Chengqian Chen, PhD, Student
Diyan Chen, PhD, Student
Guolong Zhang, PhD
Xiuli Wang, PhD
Publication date
14-12-2023

Other articles of this Issue 12/2023

Current Treatment Options in Oncology 12/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine